GLPG-2737 clinical trials
Also written GLPG2737.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses GLPG-2737 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GLPG-2737 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)TerminatedPhase 2Galapagos NVNCT04578548Written as GLPG2737
- GLPG2737 on Top of Orkambi in Subjects With Cystic FibrosisCompletedPhase 2Galapagos NVNCT03474042Written as GLPG2737
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.CompletedPhase 1Galapagos NVNCT03128606Written as GLPG3067/GLPG2222/GLPG2737 multiple dose
- Pharmacokinetics of GLPG2737 in Male Subjects With Cystic FibrosisCompletedPhase 1Galapagos NVNCT03450720Written as GLPG2737 single dose
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy SubjectsCompletedPhase 1Lakefront Biotherapeutics NVNCT03410979Written as GLPG2737 single dose